Abstract
Highly aggressive lymphomas are relatively uncommon in adults, comprising approximately 4% to 5% of all non-Hodgkin lymphomas in the United States and Western Europe. The designation of "highly aggressive" is generally restricted to precursor T-cell and B-cell lymphoblastic lymphoma/leukemia and Burkitt's lymphoma/leukemia. Treatment strategies for lymphoblastic lymphoma and Burkitt's lymphoma include complex, highly intensive combination chemotherapy regimens, which may be curative. As with other subtypes of NHL, emerging data from gene-expression profiling and related techniques are helping to define these entities more precisely and identify potential new rational therapeutic targets.
Original language | English (US) |
---|---|
Pages (from-to) | 965-978 |
Number of pages | 14 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 22 |
Issue number | 5 |
DOIs | |
State | Published - Oct 2008 |
Externally published | Yes |
Keywords
- Burkitt
- Burkitt-like
- Lymphoblastic
ASJC Scopus subject areas
- Hematology
- Oncology